MA56031A - Compositions pharmaceutiques pour le traitement du vhb - Google Patents
Compositions pharmaceutiques pour le traitement du vhbInfo
- Publication number
- MA56031A MA56031A MA056031A MA56031A MA56031A MA 56031 A MA56031 A MA 56031A MA 056031 A MA056031 A MA 056031A MA 56031 A MA56031 A MA 56031A MA 56031 A MA56031 A MA 56031A
- Authority
- MA
- Morocco
- Prior art keywords
- hbv
- treatment
- pharmaceutical compositions
- pharmaceutical
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962852705P | 2019-05-24 | 2019-05-24 | |
| US202063020927P | 2020-05-06 | 2020-05-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA56031A true MA56031A (fr) | 2022-04-06 |
Family
ID=71078646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA056031A MA56031A (fr) | 2019-05-24 | 2020-05-22 | Compositions pharmaceutiques pour le traitement du vhb |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220241208A1 (fr) |
| EP (1) | EP3975996A1 (fr) |
| JP (1) | JP2022532935A (fr) |
| KR (1) | KR20220043931A (fr) |
| CN (1) | CN114206319B (fr) |
| AU (1) | AU2020282318A1 (fr) |
| BR (1) | BR112021023622A2 (fr) |
| CA (1) | CA3140103A1 (fr) |
| MA (1) | MA56031A (fr) |
| MX (1) | MX2021014379A (fr) |
| SG (1) | SG11202112590WA (fr) |
| WO (1) | WO2020242999A1 (fr) |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106166157B (zh) | 2011-07-01 | 2019-08-02 | 巴鲁·S·布隆伯格研究所 | 作为防乙型肝炎病毒感染的抗病毒剂的氨磺酰苯甲酰胺衍生物 |
| WO2013010069A1 (fr) | 2011-07-13 | 2013-01-17 | Indiana University Research And Technology Corporation | Protéine structurale virale modifiée ayant une activité antivirale |
| US9233933B2 (en) | 2012-01-06 | 2016-01-12 | Janssen Sciences Ireland Uc | 4,4-disubstituted-1,4-dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis B |
| EA026957B1 (ru) | 2012-08-28 | 2017-06-30 | Янссен Сайенсиз Айрлэнд Юси | Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b |
| EA027280B1 (ru) | 2012-08-28 | 2017-07-31 | Янссен Сайенсиз Айрлэнд Юси | Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b |
| KR20150054795A (ko) | 2012-09-10 | 2015-05-20 | 에프. 호프만-라 로슈 아게 | B형 간염 바이러스 감염의 치료 및 예방을 위한 6-아미노산 헤테로아릴다이하이드로피리미딘 |
| WO2014074906A1 (fr) | 2012-11-09 | 2014-05-15 | Indiana University Research And Technology Corporation | Nouvelles utilisations d'effecteurs d'assemblage du vhb |
| NZ708392A (en) | 2012-12-06 | 2020-05-29 | Baruch S Blumberg Inst | Functionalized benzamide derivatives as antiviral agents against hbv infection |
| SG11201504740UA (en) | 2012-12-27 | 2015-07-30 | Univ Drexel | Novel antiviral agents against hbv infection |
| CA2899706C (fr) | 2013-02-28 | 2021-10-19 | Janssen Sciences Ireland Uc | Sulfamoyle-arylamides et utilisation connexe comme medicaments dans le traitement de l'hepatite b |
| US9895349B2 (en) | 2013-04-03 | 2018-02-20 | Janssen Sciences Ireland Us | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
| BR112015028538A2 (pt) | 2013-05-17 | 2017-07-25 | Janssen Sciences Ireland Uc | derivados de sulfamoiltiofenamida e o uso dos mesmos como medicamentos para o tratamento da hepatite b |
| CN105209470B (zh) | 2013-05-17 | 2018-02-06 | 豪夫迈·罗氏有限公司 | 用于治疗和预防乙型肝炎病毒感染的6‑桥连的杂芳基二氢嘧啶 |
| DK3116316T3 (da) * | 2014-03-13 | 2019-08-19 | Univ Indiana Res & Tech Corp | Allosteriske modulatorer af hepatitis b-kerneprotein |
| TWI730985B (zh) * | 2015-09-15 | 2021-06-21 | 美商艾森伯利生物科學公司 | B型肝炎核心蛋白質調節劑 |
| US11040965B2 (en) * | 2017-03-13 | 2021-06-22 | Assembly Biosciences, Inc. | Process for making Hepatitis B core protein modulators |
| EP3641785A1 (fr) * | 2017-06-19 | 2020-04-29 | Cellectis | Polythérapies anti-vhb impliquant des endonucléases spécifiques |
-
2020
- 2020-05-22 BR BR112021023622A patent/BR112021023622A2/pt unknown
- 2020-05-22 EP EP20732070.6A patent/EP3975996A1/fr active Pending
- 2020-05-22 MX MX2021014379A patent/MX2021014379A/es unknown
- 2020-05-22 JP JP2021569460A patent/JP2022532935A/ja active Pending
- 2020-05-22 MA MA056031A patent/MA56031A/fr unknown
- 2020-05-22 AU AU2020282318A patent/AU2020282318A1/en active Pending
- 2020-05-22 KR KR1020217041811A patent/KR20220043931A/ko unknown
- 2020-05-22 US US17/613,670 patent/US20220241208A1/en active Pending
- 2020-05-22 CN CN202080038696.0A patent/CN114206319B/zh active Active
- 2020-05-22 SG SG11202112590WA patent/SG11202112590WA/en unknown
- 2020-05-22 CA CA3140103A patent/CA3140103A1/fr active Pending
- 2020-05-22 WO PCT/US2020/034367 patent/WO2020242999A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021014379A (es) | 2022-01-06 |
| CN114206319A (zh) | 2022-03-18 |
| US20220241208A1 (en) | 2022-08-04 |
| JP2022532935A (ja) | 2022-07-20 |
| AU2020282318A1 (en) | 2021-12-02 |
| SG11202112590WA (en) | 2021-12-30 |
| CA3140103A1 (fr) | 2020-12-03 |
| KR20220043931A (ko) | 2022-04-05 |
| WO2020242999A1 (fr) | 2020-12-03 |
| EP3975996A1 (fr) | 2022-04-06 |
| CN114206319B (zh) | 2023-09-08 |
| BR112021023622A2 (pt) | 2022-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51739A (fr) | Compositions pharmaceutiques pour le traitement de la fibrose kystique | |
| MA51200A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| MA45539A (fr) | Dihydropyranopyrimidines pour le traitement d'infections virales | |
| MA49144A (fr) | Polythérapies pour le traitement du cancer | |
| MA54925A (fr) | Compositions pour le traitement de troubles acido-basiques | |
| MA49906A (fr) | Acides aminés à chaîne ramifiée pour le traitement d'une maladie du foie | |
| MA48637A (fr) | Polythérapies pour le traitement du cancer | |
| MA44737A (fr) | Compositions pour le traitement de troubles liés à l'hyperkératose | |
| MA50409A (fr) | Polythérapies pour le traitement du cancer | |
| MA56019A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| MA44413A (fr) | Composition pharmaceutique utilisée pour le traitement thérapeutique du cancer et ses complications | |
| MA50391A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de troubles inflammatoires | |
| MA44864A (fr) | Trithérapie pour le traitement d'une maladie intestinale inflammatoire | |
| MA52873A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| MA49576A (fr) | Compositions et méthodes pour le traitement d'infections fongiques | |
| MA51056A (fr) | Compositions et méthodes pour le traitement d'affections métaboliques | |
| MA44700A (fr) | Combinaison d'un anticorps anti-il-10 et d'un oligonucléotide de type cpg-c pour le traitement du cancer | |
| MA53268A (fr) | Mini-gde pour le traitement de la maladie de stockage du glycogène iii | |
| MA43825A (fr) | Schémas posologiques pour le traitement d'infections fongiques | |
| MA54522A (fr) | Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaire | |
| MA41629A (fr) | Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité | |
| MA55497A (fr) | Nouveaux composés et compositions pharmaceutiques de ceux-ci pour le traitement de troubles inflammatoires | |
| MA54873A (fr) | Compositions et méthodes pour le traitement de troubles neurocognitifs | |
| MA56031A (fr) | Compositions pharmaceutiques pour le traitement du vhb | |
| MA55093A (fr) | Méthodes et compositions pour le traitement du cancer |